The bioinformatics in in-vitro diagnostics (ivd) testing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The bioinformatics in in vitro diagnostics (IVD) testing market size has grown strongly in recent years. It will grow from $87.25 billion in 2023 to $93.02 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to improved healthcare infrastructure, expansion of biobanks, rising geriatric population, government initiatives and funding, and growth of personalized medicine.
The bioinformatics in in vitro diagnostics (IVD) testing market size is expected to see strong growth in the next few years. It will grow to $121.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising prevalence of diseases, integration of IT in healthcare, government initiatives and funding, the shift towards personalized medicine, enhanced awareness about the benefits of bioinformatics in diagnostics among healthcare providers, and the decreasing cost of genomic sequencing. Major trends in the forecast period include artificial intelligence (AI) and machine learning, next-generation sequencing, point-of-care (POC) testing, cloud computing and big data, and innovations in immunochemical techniques.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report
Scope Of Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Overview
Market Drivers –
The increasing prevalence of cancer is expected to propel the growth of the bioinformatics in IVD testing market going forward. Cancer is a broad term to describe a group of diseases characterized by abnormal cell growth that can invade and spread to other body parts. The increasing prevalence of Cancer is due to various factors related to exposure, lifestyle, and environmental influences. Bioinformatics in IVD testing transforms cancer diagnostics by providing precise, personalized, and comprehensive genetic insights that enhance early detection, treatment decisions, and patient outcomes. For instance, in May 2021, according to the National Library of Medicine, a US-based medicine library, the global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020. Therefore, the increasing prevalence of Cancer drives the bioinformatics in the IVD testing market.
Market Trends –
Major companies operating in the bioinformatics in the IVD testing market are focused on developing innovative solutions such as next-generation sequencing (NGS) technology to enhance the detection and analysis of genetic mutations, improve diagnostic accuracy, and facilitate personalized medicine approaches. Next-generation sequencing (NGS) is a high-throughput technology that allows for the rapid sequencing of entire genomes or specific regions of DNA and RNA, enabling comprehensive genetic analysis. For instance, in May 2022, Illumina Inc., a US-based biotechnology company, launched a new pan-cancer companion diagnostic (CDx) indication for its CE-marked TruSight Oncology Comprehensive (EU) test. It allows the test to identify cancer patients with solid tumors who have neurotrophic tyrosine receptor kinase (NTRK) gene fusions, including NTRK1, NTRK2, or NTRK3 and may benefit from targeted therapy with Bayer’s drug Vitrakvi (larotrectinib). The TSO Comprehensive (EU) test is a comprehensive genomic profiling (CGP) assay that includes next-generation sequencing, which analyzes multiple tumor genes and biomarkers from a single biopsy specimen to determine a patient’s specific cancer molecular profile
The bioinformatics in in-vitro diagnostics (IVD) testing market covered in this report is segmented –
1) By Type: Hardware, Software
2) By Type Of Test: Blood Based Tests, Tissue Based Tests
3) By Application: Cardiovascular Diseases, Chronic Diseases, Diabetes, Cancer, Other Applications
Get an inside scoop of the bioinformatics in in-vitro diagnostics (ivd) testing market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16629&type=smp
Regional Insights –
North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (IVD) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the bioinformatics in in-vitro diagnostics (IVD) testing market are Siemens Healthineers, International Business Machines Corporation, Medtronic Inc., Parker Hannifin Corp., Illumina Inc, PerkinElmer Inc., QIAGEN N.V., Kollmorgen Corp, Bioreference Laboratories Inc., AssureRx Health Inc., Biodesix Inc., Crescendo Bioscience Inc., Affymetrix, Complete Genomics Inc., Aperico Technologies Inc., One Lambda Inc., Datech Oncology, Life Technologies, Signal genetics, CardioDx Inc.
Table of Contents
1. Executive Summary
2. Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report Structure
3. Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Trends And Strategies
4. Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market – Macro Economic Scenario
5. Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Size And Growth
…..
27. Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
